Опыт применения ритуксимаба у больной с системным вариантом юношеского артрита

The case of early onset and severe course of systemic juvenile rheumatoid arthritis refractory to classic immunosuppressive agents and blockers of tumor necrosis factor (TNF) is presented in this article. Successful clinical use of biological agent rituximab was described. extraarticular symptoms of disease were stopped by 6 week of treatment, and acute inflammatory alteration of articulations was reduced by 16 week, the range of motions was completely restored. This case report demonstrates high activity of rituximab. A clinical and laboratory remission of disease in patient with severe course of systemic juvenile rheumatoid arthritis continues for a 32 weeks. Key words: children, juvenile rheumatoid arthritis, rituximab.